Left atrial longitudinal strain analysis in diagnostic of cardiotoxicity

Cover Page

Cite item

Full Text

Abstract

A wide range of extremely effective chemotherapy drugs has a negative effect on the cardiovascular system, leveling oncological treatment success. Early diagnosis of cardiotoxicity is very important, allowing timely application of preventive and therapeutic measures. Left ventricular ejection fraction evaluation using echocardiography is the basic non-invasive instrumental method to assess cardiac function and the main guideline in cardiac dysfunction diagnosis during chemotherapy. However, if dysfunction is subclinical, the ejection fraction can remain normal for a long time, and also has a pronounced inter-operator variability and dependence on volumetric load. Specialists are constantly in search of optimal echocardiographic parameters that allow early-stage cardiac dysfunction diagnosis. Analysis of the global longitudinal deformation of the left atrium seems to be a promising method for these purposes. A large amount of accumulated data suggests that the left atrium is not just a conduit chamber, but a reflection of the filling pressure of the left ventricle, being a sensitive marker of its systolic and diastolic dysfunction. This review presents an analysis of currently available studies on applying the methodology for assessing global longitudinal deformation of the left atrium in cardiac dysfunction diagnosis in the use of cardiotoxic drugs.

About the authors

Anastasiya V. Yusupova

Clinical Hospital of St. Luke

Author for correspondence.
Email: yusupova@lucaclinic.ru
ORCID iD: 0000-0002-0763-0537
SPIN-code: 1492-1947
Russian Federation, Saint-Petersburg

Einar S. Yusupov

North-Western District Scientific and Clinical Center named after L.G. Sokolov

Email: usupov_as@mail.ru
ORCID iD: 0000-0002-4716-0314
SPIN-code: 6632-4484

MD, Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

References

  1. Herrmann J, Lerman A, Sandhu NP, et al. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014;89(9):1287. doi: 10.1016/J.MAYOCP.2014.05.013
  2. Okwuosa TM, Anzevino S, Rao R. Cardiovascular disease in cancer survivors. Postgrad Med J. 2017;93(1096):82–90. doi: 10.1136/POSTGRADMEDJ-2016-134417
  3. Fidler MM, Reulen RC, Henson K, et al. Population-based long-term cardiac-specific mortality among 34 489 five-year survivors of childhood cancer in Great Britain. Circulation. 2017;135(10):951–963. doi: 10.1161/CIRCULATIONAHA.116.024811
  4. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and s urvivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–385. doi: 10.3322/CAAC.21565
  5. Valero-Elizondo J, Chouairi F, Khera R, et al. Atherosclerotic cardiovascular disease, cancer, and financial toxicity among adults in the United States. JACC CardioOncology. 2021;3(2):236–246. doi: 10.1016/J.JACCAO.2021.02.006
  6. Tajiri K, Aonuma K, Sekine I. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients. JJCO Japanese J Clin Oncol. 2017;47(8):678–682. doi: 10.1093/jjco/hyx068
  7. Chang HM, Moudgil R, Scarabelli T, et al. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J Am Coll Cardiol. 2017;70(20):2536–2551. doi: 10.1016/j.jacc.2017.09.1096
  8. Armstrong GT, Ross JD. Late cardiotoxicity in aging adult survivors of childhood cancer. Prog Pediatr Cardiol. 2014;36(1-2):19. doi: 10.1016/J.PPEDCARD.2014.09.003
  9. Lati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2×2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37(21):1671–1680. doi: 10.1093/eurheartj/ehw022
  10. Lopez-Mattei JC, Hassan S. The SUCCOUR trial: a cardiovascular imager’s perspective ― American College of Cardiology [Electronic resource]. Available from: https://www.acc.org/latest-in-cardiology/articles/2021/04/16/13/09/the-succour-trial. Accessed: 15.02.2022.
  11. Laufer-Perl M, Gilon D, Kapusta L, Iakobishvili Z. The role of speckle strain echocardiography in the diagnosis of early subclinical cardiac injury in cancer patients ― is there more than just left ventricle global longitudinal strain? J Clin Med. 2021;10(1):154. doi: 10.3390/JCM10010154
  12. Laufer-Pearl M, Arnold JH, Mor L, et al. The association of reduced global longitudinal strain with cancer therapy-related cardiac dysfunction among patients receiving cancer therapy. Clin Res Cardiol. 2020;109(2):255–262. doi: 10.1007/S00392-019-01508-9
  13. Choi JO, Shin DH, Cho SW, et al. Effect of preload on left ventricular longitudinal strain by 2D speckle tracking. Echocardiography. 2008;25(8):873–879. doi: 10.1111/j.1540-8175.2008.00707.x
  14. Santoro C, Arpino G, Esposito R, et al. 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility. Eur Heart J Cardiovasc Imaging. 2017;18(8):930–936. doi: 10.1093/ehjci/jex033
  15. Santoro C, Esposito R, Lembo M, et al. Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction. Eur Heart J Cardiovasc Imaging. 2019;20(12):1345–1352. doi: 10.1093/ehjci/jez194
  16. Thavendiranathan P, Negishi T, Somerset E, et al. Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll Cardiol. 2021;77(4):392–401. doi: 10.1016/j.jacc.2020.11.020
  17. Dobson R, Ghosh AK, Ky B, et al. BSE and BCOS guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab. JACC CardioOncology. 2021;3(1):1–16. doi: 10.1016/J.JACCAO.2021.01.011
  18. Kuznetsova T, Thijs L, Knez J, et al. Prognostic value of left ventricular diastolic dysfunction in a general population. J Am Hear Assoc Cardiovasc Cerebrovasc Dis. 2014;3(3):e000789. doi: 10.1161/JAHA.114.000789
  19. Nagiub M, Nixon JV, Kontos MC. Ability of nonstrain diastolic parameters to predict doxorubicin-induced cardiomyopathy: a systematic review with meta-analysis. Cardiol Rev. 2018;26(1):29–34. doi: 10.1097/CRD.0000000000000161
  20. Upshaw JN, Finkelman B, Hubbard RA, et al. Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy. JACC Cardiovasc Imaging. 2020;13(1):198–210. doi: 10.1016/J.JCMG.2019.07.018
  21. Mincu RI, Lampe LF, Mahabadi AA, et al. Left ventricular diastolic function following anthracycline-based chemotherapy in patients with breast cancer without previous cardiac disease ― a meta-analysis. J Clin Med. 2021;10(17):3890. doi: 10.3390/JCM10173890
  22. Rossi A, Temporelli PL, Quintana M, et al. Independent relationship of left atrial size and mortality in patients with heart failure: an individual patient meta-analysis of longitudinal data (MeRGE Heart Failure). Eur J Heart Fail. 2009;11(10):929–936. doi: 10.1093/EURJHF/HFP112
  23. Benjamin E, D’Agostino R, Belanger A. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation. 1995;92(4):835–841. doi: 10.1161/01.CIR.92.4.835
  24. Thomas L, Marwick HT, Popescu AB, et al. Left atrial structure and function, and left ventricular diastolic dysfunction: JACC state of the art review. J Am Coll Cardiol. 2019;73(15):1961–1977. doi: 10.1016/J.JACC.2019.01.059
  25. Serezhina EK, Obrezan AG. Significance of the echocardiographic evaluation of left atrial myocardial strain for early diagnosis of heart failure with preserved ejection fraction. Kardiologiia. 2021;61(8):68–75. (In Russ). doi: 10.18087/cardio.2021.8.n1418
  26. Kebed KY, Addetia K, Lang RM. Importance of the left atrium: more than a bystander? Heart Fail Clin. 2019;15(2):191–204. doi: 10.1016/j.hfc.2018.12.001
  27. Litwin SE. Left atrial strain: a single parameter for assessing the dark side of the cardiac cycle? JACC Cardiovasc Imaging. 2020;13(10):2114–2116. doi: 10.1016/j.jcmg.2020.07.037
  28. Alekhin МN, Kalinin АО. Diastolic function of the left ventricle: the meaning of left atrium longitudinal strain. Ultrasound Funct Diagnostics. 2020;(3):91–104. (In Russ). doi: 10.24835/1607-0771-2020-3-91-104
  29. Szilveszter B, Nagy AI, Vattay B, et al. Left ventricular and atrial strain imaging with cardiac computed tomography: validation against echocardiography. J Cardiovasc Comput Tomogr. 2020;14(4):363–369. doi: 10.1016/j.jcct.2019.12.004
  30. Kim J, Yum B, Palumbo MC, et al. Left atrial strain impairment precedes geometric remodeling as a marker of post-myocardial infarction diastolic dysfunction. JACC Cardiovasc Imaging. 2020;13(10):2099–2113. doi: 10.1016/j.jcmg.2020.05.041
  31. Pathan F, Zainal Abidin HA, Vo QH, et al. Left atrial strain: a multi-modality, multi-vendor comparison study. Eur Heart J Cardiovasc Imaging. 2021;22(1):102–110. doi: 10.1093/ehjci/jez303
  32. Genovese D, Singh A, Volpato V, et al. Load dependency of left atrial strain in normal subjects. J Am Soc Echocardiogr. 2018;31(11):1221–1228. doi: 10.1016/j.echo.2018.07.016
  33. Brecht A, Oertelt-Prigione S, Seeland U, et al. Left Atrial function in preclinical diastolic dysfunction: two-dimensional speckle-tracking echocardiography ― derived results from the BEFRI trial. J Am Soc Echocardiogr. 2016;29(8):750–758. doi: 10.1016/j.echo.2016.03.013
  34. Lundberg A, Johnson J, Hage C, et al. Left atrial strain improves estimation of filling pressures in heart failure: a simultaneous echocardiographic and invasive haemodynamic study. Clin Res Cardiol. 2019;108:703–715. doi: 10.1007/s00392-018-1399-8
  35. Mandoli GE, Sisti N, Mondillo S, et al. Left atrial strain in left ventricular diastolic dysfunction: have we finally found the missing piece of the puzzle? Heart Fail Rev. 2020;25(3):409–417. doi: 10.1007/s10741-019-09889-9
  36. Pathan F, D’Elia N, Nolan MT, et al. Normal ranges of left atrial strain by speckle-tracking echocardiography: a systematic review and meta-analysis. J Am Soc Echocardiogr. 2017;30(1):59–70.e8. doi: 10.1016/j.echo.2016.09.007
  37. Monte I, Bottari V, Buccheri S, et al. Chemotherapy-induced cardiotoxicity: subclinical cardiac dysfunction evidence using speckle tracking echocardiography. J Cardiovasc Echogr. 2013;23(1):33–38. doi: 10.4103/2211-4122.117983
  38. Sonaglioni A, Albini A, Fossile E, et al. Speckle-tracking echocardiography for cardioncological evaluation in bevacizumab-treated colorectal cancer patients. Cardiovasc Toxicol. 2020;20(6):581–592. doi: 10.1007/s12012-020-09583-5
  39. Meloche J, Nolan M, Amir E, et al. Temporal changes in left atrial function in women with HER2+ breast cancer receivig sequential anthracyclines and trastuzumab therapy. J Am Coll Cardiol. 2018;71(11):A1524. doi: 10.1016/s0735-1097(18)32065-5
  40. Emerson P, Stefani L, Terluk A, et al. Left atrial strain analysis in breast cancer patients post anthracycline (AC). Hear Lung Circ. 2021;30:S196. doi: 10.1016/j.hlc.2021.06.225
  41. Laufer-Perl M, Arias O, Dorfman SS, et al. Left atrial strain changes in patients with breast cancer during anthracycline therapy. Int J Cardiol. 2021;330:238–244. doi: 10.1016/J.IJCARD.2021.02.013
  42. Moustafa S, Murphy K, Nelluri BK, et al. Temporal trends of cardiac chambers function with trastuzumab in human epidermal growth factor receptor ii-positive breast cancer patients. Echocardiography. 2016;33(3):406–415. doi: 10.1111/echo.13087
  43. Moreno J, García-Sáez JA, Clavero M, et al. Effect of breast cancer cardiotoxic drugs on left atrial myocardium mechanics. Searching for an early cardiotoxicity marker. Int J Cardiol. 2016;210:32–34. doi: 10.1016/j.ijcard.2016.02.093
  44. Setti E, Dolci G, Bergamini C, et al. P2460 prospective evaluation of atrial function by 2D speckle tracking analysis in HER-2 positive breast cancer patients during Trastuzumab therapy. Eur Heart J. 2019;40(Suppl 1):2460. doi: 10.1093/eurheartj/ehz748.0792
  45. Moustafa S, Ho TH, Shah P, et al. Predictors of Incipient dysfunction of all cardiac chambers after treatment of metastatic renal cell carcinoma by tyrosine kinase inhibitors. J Clin Ultrasound. 2016;44(4):221. doi: 10.1002/JCU.22333
  46. Anqi Y, Yu Z, Mingjun X, et al. Use of echocardiography to monitor myocardial damage during anthracycline chemotherapy. Echocardiography. 2019;36(3):495–502. doi: 10.1111/echo.14252
  47. Timóteo AT, Moura Branco L, Filipe F, et al. Cardiotoxicity in breast cancer treatment: What about left ventricular diastolic function and left atrial function? Echocardiography. 2019;36(10):1806–1813. doi: 10.1111/echo.14487
  48. Park H, Kim KH, Kim HY, et al. Left atrial longitudinal strain as a predictor of cancer therapeutics-related cardiac dysfunction in patients with breast cancer. Cardiovasc Ultrasound. 2020;18(1):1–8. doi: 10.1186/S12947-020-00210-5
  49. Di Lisi D, Cadeddu Dessalvi C, Manno G, et al. Left atrial strain and left atrial stiffness for early detection of cardiotoxicity in cancer patients. Eur Heart J. 2021;42(Suppl 1):2021. doi: 10.1093/eurheartj/ehab724.021
  50. Li VW, Lai CT, Liu AP, et al. Left atrial mechanics and integrated calibrated backscatter in anthracycline-treated long-term survivors of childhood cancers. Ultrasound Med Biol. 2017;43(9):1897–1905. doi: 10.1016/j.ultrasmedbio.2017.05.017
  51. Loar RW, Colquitt JL, Rainusso NC, et al. Assessing the left atrium of childhood cancer survivors. Int J Cardiovasc Imaging. 2021;37(1):155–162. doi: 10.1007/s10554-020-01970-x
  52. Patel NR, Chyu CK, Satou GM, et al. Left atrial function in children and young adult cancer survivors treated with anthracyclines. Echocardiography. 2018;35(10):1649–1656. doi: 10.1111/echo.14100
  53. Tadic M, Genger M, Cuspidi C, et al. Phasic left atrial function in cancer patients before initiation of anti-cancer therapy. J Clin Med. 2019;8(4):421. doi: 10.3390/JCM8040421
  54. Liao JN, Chao TF, Kuo JY, et al. Age, sex, and blood pressure-related influences on reference values of left atrial deformation and mechanics from a large-scale asian population. Circ Cardiovasc Imaging. 2017;10(10):e006077. doi: 10.1161/CIRCIMAGING.116.006077
  55. Cameli M, Mandoli GE, Loiacono F, et al. Left atrial strain: a new parameter for assessment of left ventricular filling pressure. Heart Fail Rev. 2016;21(1):65–76. doi: 10.1007/S10741-015-9520-9
  56. Singh A, El Hangouche N, McGee K, et al. Utilizing left atrial strain to identify patients at risk for atrial fibrillation on ibrutinib. Echocardiography. 2021;38(1):81–88. doi: 10.1111/echo.14946

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Yusupova A.V., Yusupov E.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies